Hide metadata

dc.contributor.authorDesikan, Rahul S
dc.contributor.authorThompson, Wesley K
dc.contributor.authorHolland, Dominic
dc.contributor.authorHess, Christopher P
dc.contributor.authorBrewer, James B
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorBlennow, Kaj
dc.contributor.authorAndreassen, Ole A
dc.contributor.authorMcEvoy, Linda K
dc.contributor.authorHyman, Bradley T
dc.contributor.authorDale, Anders M
dc.date.accessioned2015-10-20T10:50:43Z
dc.date.available2015-10-20T10:50:43Z
dc.date.issued2013
dc.identifier.citationMolecular Neurodegeneration. 2013 Oct 02;8(1):39
dc.identifier.urihttp://hdl.handle.net/10852/46908
dc.description.abstractBackground Epidemiological and molecular findings suggest a relationship between Alzheimer’s disease (AD) and dyslipidemia, although the nature of this association is not well understood. Results Using linear mixed effects models, we investigated the relationship between CSF levels of heart fatty acid binding protein (HFABP), a lipid binding protein involved with fatty acid metabolism and lipid transport, amyloid-β (Aβ), phospho-tau, and longitudinal MRI-based measures of brain atrophy among 295 non-demented and demented older individuals. Across all participants, we found a significant association of CSF HFABP with longitudinal atrophy of the entorhinal cortex and other AD-vulnerable neuroanatomic regions. However, we found that the relationship between CSF HABP and brain atrophy was significant only among those with low CSF Aβ1–42 and occurred irrespective of phospho-tau181p status. Conclusions Our findings indicate that Aβ-associated volume loss occurs in the presence of elevated HFABP irrespective of phospho-tau. This implicates a potentially important role for fatty acid binding proteins in Alzheimer’s disease neurodegeneration.
dc.language.isoeng
dc.rightsDesikan et al.; licensee BioMed Central Ltd.
dc.rightsAttribution 2.0 Generic
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/
dc.titleHeart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration
dc.typeJournal article
dc.date.updated2015-10-20T10:50:44Z
dc.creator.authorDesikan, Rahul S
dc.creator.authorThompson, Wesley K
dc.creator.authorHolland, Dominic
dc.creator.authorHess, Christopher P
dc.creator.authorBrewer, James B
dc.creator.authorZetterberg, Henrik
dc.creator.authorBlennow, Kaj
dc.creator.authorAndreassen, Ole A
dc.creator.authorMcEvoy, Linda K
dc.creator.authorHyman, Bradley T
dc.creator.authorDale, Anders M
dc.identifier.doihttp://dx.doi.org/10.1186/1750-1326-8-39
dc.identifier.urnURN:NBN:no-51073
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46908/1/13024_2013_Article_486.pdf
dc.type.versionPublishedVersion
cristin.articleid39


Files in this item

Appears in the following Collection

Hide metadata

Attribution 2.0 Generic
This item's license is: Attribution 2.0 Generic